- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05141981
Sarcopenia and Its Associated Factors Among Hip Fractures Patients
November 30, 2021 updated by: AHAbdelhafeez, Assiut University
Sarcopenia and Its Associated Factors Among Hip Fracture Patients in Assuit University Trauma Hospital
- Asses the prevalence of sarcopenia in hip fracture patients in Truama hospital at Assuit University
- To study the associated factors of sarcopenia in hip fracture patients in Trauma hospital at Assuit University
Study Overview
Detailed Description
Skeletal muscle is the largest body compartment in most adults with the exception of an enlarged adipose tissue mass in the presence of obesity.
Skeletal muscles grow in size from birth onward, reaching peak mass in the third decade.
Many factors determine an individual adult's total body skeletal muscle mass and include their size(height),magnitude of adiposity, race, genetic factors, activity, hormone levels and diet.
By the fourth decade populations and individuals begin to show a gradual loss in skeletal muscle mass and the rate of atrophy appears to accelerate beyond the seventh decade.
The senescence-related changes in skeletal muscle are, in turn, associated with adverse out- comes such as pathological bone fractures and even death.
The term sarcopenia, from the Greek roots is widely used to describe the age-associated decrease in muscle mass observed in several cross-sectional and longitudinal studies.
Interest in sarcopenia mainly results from its linkage with unfavorable outcomes, including mobility disorders, increased risk of falling, reduced ability to function in activities of daily living, loss of independence, poor quality of life, and reduced life expectancy.
Measuring skeletal muscle mass, composition, strength and physical performance is thus a vital part of not only studying sarcopenia, but also of growing importance in clinically evaluating and monitoring the greatly increasing population of ageing at risk adults in most countries.
Our report highlights aspects of evaluating these features of skeletal muscle and expands on earlier methodological and historical reviews.
While the main phenotypic feature of sarcopenia is loss of lean tissue, notably skeletal muscle, there is growing recognition that sarcopenia can co-exist in the presence of obesity.
A skeletal muscle compartment reduced in mass may thus be masked by the presence of excess fat.
Diagnosing sarcopenia-obesity may thus include measures beyond that of skeletal muscle mass such as BMI and total body fat, topics that we will allude to in the review that follows.
Loss of skeletal muscle also plays an important role in two other conditions, cachexia and frailty, creating a spectrum of phenotypes and clinical conditions that encompass sarcopenia There are two main factors for Skeletal muscle evaluation, skeletal muscle mass and composition, are the main determinants of global muscle metabolic function, strength and physical performance.
Vascular and neurological integrity are also essential components that ultimately contribute to a skeletal muscle's metabolic and mechanical functionality.
The'quality' of a skeletal muscle is a loosely defined concept that broadly includes aspects of anatomic structure, chemical composition and metabolic and mechanical performance.
Our review encompasses aspects of measuring skeletal muscle mass, composition and function in relation to the evaluation of individuals and groups for the presence of sarcopenia and related conditions.
Multiple methods of measuring skeletal muscle mass are available for research and clinical purposes that vary in cost, complexity and availability.
A high prevalence of low muscle mass in hip-fracture patients has been shown.
Hip fractures carry a high risk of both death and disability with a 8-36 % excess mortality within 1 year and more than 50 % of the survivors not regaining their own pre-injury level of independence.
Sarcopenia may worsen the functional prognosis after hip fracture occurrence, but the association between reduced muscle mass and functional ability remains unclear in this group of older and frail persons.
Conversely, muscle strength has been indicated as a strong independent predictor of the functional outcome, whereas lower-limb performance is usually not accessible at an early stage, because of the direct consequences of the hip fracture on ambulation.
There are no available studies in our locality about sarcopenia and its related factors
Study Type
Observational
Enrollment (Anticipated)
152
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Abdelhafeez hamdi
- Phone Number: 00201002809764
- Email: abdoofiz@yahoo.com
Study Contact Backup
- Name: Dalia Galal, prof
- Phone Number: 00201007120821
- Email: daliaym2001@yahoo.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
admitted patients in Assiut university Truama hospital
Description
Inclusion Criteria:
- old patients >50 years with hip fracture attending assuit university hospital
Exclusion Criteria:
- patients with dementia ,muscle disease and neurological disease
- Patients who are unwilling to participate
- Patients>80 years due to uncooperate at this age to answer the questionnaire
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of Sarcopenia among Hip fracture patients in Assuit University Truama hospital
Time Frame: 20 minutes
|
by dexa scan
|
20 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Osama Ahmad, prof, assuit yniversity
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2022
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
June 1, 2023
Study Registration Dates
First Submitted
September 20, 2021
First Submitted That Met QC Criteria
November 30, 2021
First Posted (Actual)
December 2, 2021
Study Record Updates
Last Update Posted (Actual)
December 2, 2021
Last Update Submitted That Met QC Criteria
November 30, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- sarcopenia and hip fracure
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on dexa scan
-
Northern Orthopaedic Division, DenmarkTerminated
-
Marwa Hassan Abdelhamed HassanAssiut UniversityNot yet recruitingEvaluate Bone Denisty Changes in Children With Beta Thalassemia Major
-
Akron Children's HospitalAlfred I. duPont Hospital for Children; University of North Carolina; Kent State...CompletedCerebral Palsy | Bone Density
-
University of BedfordshireUnknown
-
Assiut UniversityNot yet recruiting
-
Montefiore Medical CenterRecruiting
-
State University of New York - Upstate Medical...Enrolling by invitation
-
Assistance Publique - Hôpitaux de ParisSidactionCompleted
-
Assiut UniversityNot yet recruitingParathyroid Diseases | CKD | Thyroid